Evommune reported that EVO301, an IL‑18–binding long‑acting fusion protein, met primary endpoints in a Phase 2a atopic dermatitis study, delivering statistically significant EASI improvements versus placebo. The topline drove a sharp premarket share rally and positioned EVO301 as a potential alternative to current IL‑4/13 and IL‑13 agents. Evommune plans a Phase 2b to test subcutaneous formulations and optimized dosing; management said higher or more frequent dosing could further improve efficacy. The result tightens competition in the eczema biologic market and underscores investor interest in differentiated cytokine‑targeting approaches.